US Bancorp’s Cullinan Oncology CGEM Stock Holding History

US Bancorp’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.13K	Buy	502 +19	+4%	+$244	﹤0.01%	3471
2025 Q4	$5K	Buy	+483	New	+$4.36K	﹤0.01%	3531
2025 Q3	–	Sell	-295	Closed	-$2.22K	–	4057
2025 Q2	$2.22K	Sell	295 -1,262	-81%	-$10.1K	﹤0.01%	3852
2025 Q1	$11.8K	Buy	1,557 +1,344	+631%	+$12.9K	﹤0.01%	3380
2024 Q4	$2.6K	Buy	213 +96	+82%	+$1.38K	﹤0.01%	3806
2024 Q3	$1.96K	Buy	117 +12	+11%	+$213	﹤0.01%	3790
2024 Q2	$1.83K	Sell	105 -323	-75%	-$6.88K	﹤0.01%	3734
2024 Q1	$7.29K	Sell	428 -76	-15%	-$1.17K	﹤0.01%	3427
2023 Q4	$5.14K	Buy	+504	New	+$4.46K	﹤0.01%	3521
2023 Q2	–	Sell	-1,084	Closed	-$11.1K	–	4009
2023 Q1	$11.1K	Buy	1,084 +517	+91%	+$5.7K	﹤0.01%	3242
2022 Q4	$5.98K	Sell	567 -110	-16%	-$1.34K	﹤0.01%	3453
2022 Q3	$9K	Buy	677 +186	+38%	+$2.51K	﹤0.01%	3390
2022 Q2	$6K	Sell	491 -1,267	-72%	-$14.4K	﹤0.01%	3511
2022 Q1	$18K	Buy	1,758 +308	+21%	+$4.16K	﹤0.01%	3127
2021 Q4	$22K	Buy	1,450 +1,440	+14,400%	+$28.7K	﹤0.01%	3060
2021 Q3	$0	Buy	+10	New	+$267	﹤0.01%	4087

Other funds holding CGEM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

US Bancorp's CGEM Position: Q1 2026 in Review

US Bancorp increased its Cullinan Oncology (CGEM) stake by 3.9% in Q1 2026, buying an estimated $244 and bringing the position to 502 shares worth $7.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3471.

US Bancorp first reported a position in CGEM in Q3 2021 and has held it in 16 quarters since. The position peaked at $22K in Q4 2021. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

US Bancorp held 502 shares of Cullinan Oncology worth $7.13K as of Q1 2026.
US Bancorp bought 19 Cullinan Oncology shares in Q1 2026, an estimated $244.
Cullinan Oncology made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3471 holding.
US Bancorp first reported a position in Cullinan Oncology in Q3 2021 and has held it in 16 quarters since.
US Bancorp's Cullinan Oncology position peaked at $22K in Q4 2021.
174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.